Tiloron

General characteristics. Structure:

Active ingredient: тилорон (in terms of 100% substance) - 125 mg; 

Excipients: cellulose microcrystallic (Vivapur type 102), коповидон (Plasdon S-630), silicon dioxide colloid (Aerosil), calcium stearate, capsules firm gelatinous No. 1 (titanium E-171 dioxide, gelatin, dye sunset yellow E-110).

Description: Capsules gelatinous firm No. 1 of orange color. Contents of capsules - the granulate containing granules and powder of orange color impregnations from light orange till dark orange color are allowed.

Pharmacological properties:

Pharmacodynamics. The low-molecular synthetic inductor of interferon stimulating education in an organism of interferon an alpha, a beta and scale. The main producers of interferon in response to introduction of a tiloron are intestines epithelium cells, hepatocytes, T lymphocytes, neutrophils and granulocytes. After intake at most of products of interferon intestines - a liver - blood are defined by 4-24 h in the sequence. In leukocytes of the person induces interferon synthesis.  Stimulates stem cells of marrow, depending on a dose strengthens antibodyformation, reduces immunosuppression degree, recovers ratios of T-suppressors and T-helperov. The mechanism of antiviral action is connected with inhibition of broadcast of virus-specific proteins in the infected cells therefore the reproduction of viruses is suppressed. It is effective concerning causative agents of a viral hepatitis, gerpesvirus (including cytomegaloviruses).

Pharmacokinetics. After intake it is quickly soaked up from digestive tract. Bioavailability - 60%. About 80% of drug contact proteins of plasma. Drug practically in not changed view with excrements (70%) and with urine (9%) is removed. T1/2 - 48 h. Drug is not exposed to metabolism and does not kumulirut.

Indications to use:

At adults: a viral hepatitis And, In, With, a herpes and Cytomegaloviral infection, complex therapy: infectious and allergic and viral encephalomyelitis (multiple sclerosis, a leukoencephalitis, uveoentsefalit), chlamydial infections of an urogenital and respiratory path; prevention of flu, etc. Acute respiratory viral infection.

Route of administration and doses:

Inside, after food, with the preventive purpose - on 125 mg once a week during 4-6 weeks, with medical - on 125-250 mg/days within 1-2 days, then on 125 mg in 48 h. Course of treatment: flu and other acute respiratory viral infections at adults - 1 week; hepatitis A - 2-3 weeks; hepatitis B - 3-4 weeks; herpes, Cytomegaloviral and chlamydial infections and their combinations - 4 weeks. A chronic viral hepatitis In and With, hepatitises-mikst - on 250 mg 2 times a week, a course of treatment - 2-4 weeks. Secondary immunodeficiences and disturbances of the interferon status - on 125 mg 2 times a week. A course of treatment - 2-4 weeks. Multiple sclerosis - on 125 mg in 48 h (only 10 capsules).

Side effects:

Allergic reactions. Dispeptic phenomena, short-term fever.

Interaction with other medicines:

Let's combine with antibiotics, medicines for treatment of viral and bacterial diseases.

Contraindications:

Hypersensitivity, pregnancy, the lactation period, children's age (up to 7 years).

Storage conditions:

List B. In the dry, protected from light place at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

Without recipe

Packaging:

Capsules of 125 mg. 6 or 10 capsules in a blister strip packaging from a film of PVC and a foil. 1 blister strip packaging together with the application instruction in a pack from a cardboard.